RUNX1 and acute myeloid leukemia: In our study, OCI-AML-2 (expressing NPM1-wt) and OCI-AML-3 (expressing the type A mutation of NPMc+ and the DNMT3A R882C mutation of a DNA methyltransferase) cells are employed for intracellular analysis of NPM1-related AML1,36.